Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2019 07:30 ET | Source: TESARO, Inc.

TESARO Announces Data Presentations at the 2019 SGO Annual Meeting on Women’s Cancer

WALTHAM, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- TESARO, an oncology-focused business within GSK, today announced that data for dostarlimab (anti-PD-1 antibody, formerly TSR-042) and Zejula®...
February 26, 2019 07:30 ET | Source: TESARO, Inc.

Actor Scott Foley and TESARO Team Up to Empower Ovarian Cancer Care Partners Through New Phase of Not on My Watch Movement

WALTHAM, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- TESARO, Inc., an oncology-focused business within GSK, announced today that acclaimed actor Scott Foley (TV’s Felicity, Scandal and the new ABC...
January 24, 2019 08:00 ET | Source: TESARO, Inc.

TESARO, Inc. Provides Notice of Fundamental Change, Conversion Rate Adjustment pursuant to Make-Whole Adjustment Event and Supplemental Indenture

WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- TESARO, Inc. (the “Company” or “TESARO”), an oncology-focused biopharmaceutical company, today announced that pursuant to the terms of the Indenture...
December 04, 2018 16:15 ET | Source: TESARO, Inc.

TESARO, Inc. Gives Notice of Anticipated Make-Whole Adjustment Event to Holders of Its Convertible Senior Notes

WALTHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that, pursuant to the terms of the indenture (the...
December 03, 2018 07:04 ET | Source: TESARO, Inc.

GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company

LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive...
November 09, 2018 15:41 ET | Source: TESARO, Inc.

TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting

Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combination with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1 treatmentTSR-042...
November 01, 2018 16:05 ET | Source: TESARO, Inc.

TESARO Announces Third-Quarter 2018 Operating Results

ZEJULA® Q3 net sales totaled $63 million compared to $39 million for Q3 2017Top-line results for PRIMA trial of ZEJULA monotherapy for first-line ovarian cancer patients regardless of BRCA mutation...
October 30, 2018 08:05 ET | Source: TESARO, Inc.

The Foundation for Women’s Cancer and TESARO Partner on the Race to End Women’s Cancer for 3rd Year

CHICAGO and WALTHAM, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), and TESARO, Inc....
October 29, 2018 08:00 ET | Source: TESARO, Inc.

TESARO Announces Achievement of ZEJULA Prostate Cancer Development Milestones by Janssen

WALTHAM, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced the achievement of development milestones that trigger...
October 24, 2018 08:00 ET | Source: TESARO, Inc.

TESARO and Actress Cobie Smulders Launch Not on My Watch, a National Movement to Empower the Ovarian Cancer Community

Not on My Watch Aims to Shine a Light on the Importance of an Informed, Proactive Approach to Treatment WALTHAM, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an...

Next Page keyboard_arrow_right